{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:15:46Z","timestamp":1754108146275},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:00:00Z","timestamp":1506384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0185342","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T17:30:37Z","timestamp":1506447037000},"page":"e0185342","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1"],"prefix":"10.1371","volume":"12","author":[{"given":"Willem G.","family":"van Ginkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danique","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes G. M.","family":"Burgerhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim","family":"de Blaauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Estela","family":"Rubio Gozalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Rebecca","family":"Heiner-Fokkema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francjan J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-8","article-title":"Recommendations for the management of tyrosinaemia type 1","volume":"8","author":"C de Laet","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"8823","key":"ref2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","article-title":"Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase","volume":"340","author":"S Lindstedt","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1005410820201","article-title":"Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)","volume":"21","author":"E Holme","year":"1998","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","article-title":"Tyrosinemia: a review","volume":"4","author":"PA Russo","year":"2001","journal-title":"Pediatr Dev Pathol"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1023\/A:1005666426079","article-title":"Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia","volume":"23","author":"CJ Wilson","year":"2000","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1469-8749.2011.04048.x","article-title":"Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1","volume":"53","author":"C De Laet","year":"2011","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-277X.2011.01215.x","article-title":"Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?","volume":"25","author":"A Daly","year":"2012","journal-title":"J Hum Nutr Diet"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1007\/8904_2014_358","article-title":"Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented?","author":"D van Vliet","year":"2014","journal-title":"JIMD Rep"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10545-008-0793-1","article-title":"NTBC treatment in tyrosinaemia type I: long-term outcome in French patients","volume":"31","author":"A Masurel-Paulet","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"ref10","first-page":"96","article-title":"Behavioral and intellectual functioning in patients with tyrosinemia type I","volume":"18","author":"M Pohorecka","year":"2012","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-011-9394-5","article-title":"Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC","volume":"35","author":"E Thimm","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jpeds.2013.10.001","article-title":"Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone","volume":"164","author":"F Bendadi","year":"2014","journal-title":"J Pediatr"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0472-5","article-title":"Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls","volume":"11","author":"WG van Ginkel","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2010.11.003","article-title":"Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I","volume":"102","author":"E Thimm","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejps.2008.06.015","article-title":"Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2","volume":"35","author":"EM del Amo","year":"2008","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(01)01810-9","article-title":"Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature","volume":"306","author":"DM Killian","year":"2001","journal-title":"Neurosci Lett"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1471-4159.1987.tb01039.x","article-title":"Kinetics of neutral amino acid transport across the blood-brain barrier","volume":"49","author":"QR Smith","year":"1987","journal-title":"J Neurochem"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1023\/A:1022482604276","article-title":"Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids","volume":"23","author":"WM Pardridge","year":"1998","journal-title":"Neurochem Res"},{"issue":"4S Suppl","key":"ref19","doi-asserted-by":"crossref","first-page":"1016S","DOI":"10.1093\/jn\/130.4.1016S","article-title":"Transport of glutamate and other amino acids at the blood-brain barrier","volume":"130","author":"QR Smith","year":"2000","journal-title":"J Nutr"},{"issue":"4059","key":"ref20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.178.4059.414","article-title":"Brain serotonin content: physiological regulation by plasma neutral amino acids","volume":"178","author":"JD Fernstrom","year":"1972","journal-title":"Science"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"e0143833","DOI":"10.1371\/journal.pone.0143833","article-title":"Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice","volume":"10","author":"D van Vliet","year":"2015","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-9-73","article-title":"Brain-blood amino acid correlates following protein restriction in murine maple syrup urine disease","volume":"9","author":"KR Vogel","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/mgme.2001.3257","article-title":"Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation","volume":"74","author":"A Schulze","year":"2001","journal-title":"Mol Genet Metab"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ymgme.2009.12.007","article-title":"Classical maple syrup urine disease and brain development: principles of management and formula design","volume":"99","author":"KA Strauss","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"ref25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2015.05.011","article-title":"Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome","volume":"116","author":"CR,2nd Coughlin","year":"2015","journal-title":"Mol Genet Metab"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-9-7","article-title":"Single amino acid supplementation in aminoacidopathies: a systematic review","volume":"9","author":"D van Vliet","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"36","key":"ref27","doi-asserted-by":"crossref","first-page":"19392","DOI":"10.1016\/S0021-9258(19)77645-5","article-title":"Neutral amino acid transport at the human blood-brain barrier","volume":"263","author":"KM Hargreaves","year":"1988","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"ref28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2011.07.003","article-title":"Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx","volume":"104","author":"KA Strauss","year":"2011","journal-title":"Mol Genet Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0185342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T13:34:39Z","timestamp":1659533679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0185342"}},"subtitle":[],"editor":[{"given":"James D.","family":"Clelland","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,26]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0185342","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,26]]}}}